412 related articles for article (PubMed ID: 33854479)
1. Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.
Patel M; Tena I; Jha A; Taieb D; Pacak K
Front Endocrinol (Lausanne); 2021; 12():625312. PubMed ID: 33854479
[TBL] [Abstract][Full Text] [Related]
2. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas.
Leijon H; Remes S; Hagström J; Louhimo J; Mäenpää H; Schalin-Jäntti C; Miettinen M; Haglund C; Arola J
Hum Pathol; 2019 Apr; 86():66-75. PubMed ID: 30529752
[TBL] [Abstract][Full Text] [Related]
3. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.
Severi S; Bongiovanni A; Ferrara M; Nicolini S; Di Mauro F; Sansovini M; Lolli I; Tardelli E; Cittanti C; Di Iorio V; Mezzenga E; Scarpi E; Ibrahim T; Paganelli G; Zovato S
ESMO Open; 2021 Aug; 6(4):100171. PubMed ID: 34139487
[TBL] [Abstract][Full Text] [Related]
4. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
5. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.
Carrasquillo JA; Chen CC; Jha A; Pacak K; Pryma DA; Lin FI
J Nucl Med; 2021 Sep; 62(9):1192-1199. PubMed ID: 34475242
[TBL] [Abstract][Full Text] [Related]
6. Performance of
Han S; Suh CH; Woo S; Kim YJ; Lee JJ
J Nucl Med; 2019 Mar; 60(3):369-376. PubMed ID: 30030341
[TBL] [Abstract][Full Text] [Related]
7. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
8.
Kan Y; Zhang S; Wang W; Liu J; Yang J; Wang Z
Acta Radiol; 2018 Dec; 59(12):1466-1474. PubMed ID: 29566550
[TBL] [Abstract][Full Text] [Related]
9. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma.
Jungels C; Karfis I
Curr Opin Oncol; 2021 Jan; 33(1):33-39. PubMed ID: 33093336
[TBL] [Abstract][Full Text] [Related]
10. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
11. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas.
Elston MS; Meyer-Rochow GY; Conaglen HM; Clarkson A; Clifton-Bligh RJ; Conaglen JV; Gill AJ
Hum Pathol; 2015 Mar; 46(3):390-6. PubMed ID: 25554089
[TBL] [Abstract][Full Text] [Related]
12. Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Rubino M; Di Stasio GD; Bodei L; Papi S; Rocca PA; Ferrari ME; Fodor CI; Bagnardi V; Frassoni S; Mei R; Fazio N; Ceci F; Grana CM
Endocrine; 2024 May; 84(2):704-710. PubMed ID: 38324106
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma.
Zhang X; Wakabayashi H; Hiromasa T; Kayano D; Kinuya S
Semin Nucl Med; 2023 Jul; 53(4):503-516. PubMed ID: 36641337
[TBL] [Abstract][Full Text] [Related]
14. The utility of
Jaiswal SK; Sarathi V; Malhotra G; Hira P; Shah R; Patil VA; Dalvi A; Prakash G; Lila AR; Shah NS; Bandgar T
J Pediatr Endocrinol Metab; 2021 Jan; 34(1):109-119. PubMed ID: 33180042
[TBL] [Abstract][Full Text] [Related]
15. Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model.
Ullrich M; Bergmann R; Peitzsch M; Zenker EF; Cartellieri M; Bachmann M; Ehrhart-Bornstein M; Block NL; Schally AV; Eisenhofer G; Bornstein SR; Pietzsch J; Ziegler CG
Theranostics; 2016; 6(5):650-65. PubMed ID: 27022413
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
[TBL] [Abstract][Full Text] [Related]
17. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
[TBL] [Abstract][Full Text] [Related]
18. Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.
Saveanu A; Muresan M; De Micco C; Taieb D; Germanetti AL; Sebag F; Henry JF; Brunaud L; Enjalbert A; Weryha G; Barlier A
Endocr Relat Cancer; 2011 Apr; 18(2):287-300. PubMed ID: 21335363
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB
AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455
[No Abstract] [Full Text] [Related]
20. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
Taïeb D; Jha A; Treglia G; Pacak K
Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
